

Media release

Zug, 15 February 2018

HBM Healthcare Investments portfolio company, TandemLife, to be acquired for up to USD 250 million in cash

TandemLife (also known as CardiacAssist, Inc.), a privately held company in the portfolio of HBM Healthcare Investments, entered into an acquisition agreement for up to USD 250 million yesterday. The agreement with LivaNova PLC (NASDAQ:LIVN) consists of upfront payments of USD 200 million and up to USD 50 million in contingent considerations based on regulatory milestones. The deal is projected to close in early to mid-2018, subject to approvals and other customary closing conditions.

HBM Healthcare Investments has been a shareholder of TandemLife since 2003 and currently owns approximately 16.6 percent of the company.

The Pittsburgh-based company TandemLife developed the world's first FDA-cleared and CE-marked short-term extracorporeal circulatory support platform. TandemLife products have provided critical cardiopulmonary support to thousands of patients in top hospitals worldwide. Today, TandemLife offers a range of solutions for advanced cardiopulmonary temporary support, all built around a common pump and controller. LivaNova is a global medical technology company headquartered in London, operating with three business franchises: Cardiac Surgery, Neuromodulation and Cardiac Rhythm Management.

For further information, please contact Dr. Andreas Wicki, Tel. +41 41 710 75 77, andreas.wicki@hbmhealthcare.com

Information on HBM Healthcare Investments Ltd.

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA



companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.